The Life Science Feed
Deep dives with clinicians, researchers, and industry leaders.
All episodes
Prostate Care: Balancing Immediate Relief with Long-Term Retreatment
Managing benign prostatic hyperplasia requires weighing rapid symptom improvement against the need for future interventions. Clinicians must consider patient preference and disease progression.
Lung NeoplasmsHalf of Older Adults With Metastatic Lung Cancer Receive No Systemic Treatment
A significant proportion of older adults diagnosed with metastatic non-small cell lung cancer receive no systemic treatment, highlighting a critical care gap.
Solid TumorsWearable Devices Detect CAR-T CRS Hours Earlier, Improving Patient Outcomes
Wearable devices identify cytokine release syndrome (CRS) in CAR-T cell therapy recipients hours before clinical recognition, enabling earlier intervention and potentially reducing severe complications.
Alpha-Emitting Radioantibody Lowers PSA in CRPC
Genetic Test Identifies Breast Cancer Patients Who May Avoid Chemotherapy
Bowhead Whale Longevity Genes Offer Clues for Cancer, Aging
Men Face Later Cancer Diagnoses Across 20 Types
Tucatinib Extends PFS in HER2-Positive Breast Cancer, No New Safety Signals
Giredestrant Improves Breast Cancer Survival Regardless of Menopause
EASL Congress 2026: Key Trials to Watch in Liver Disease Management
EASL Congress 2026 will feature pivotal trials in NAFLD/NASH, HBV, and HCC, potentially reshaping current treatment paradigms.
Liver CirrhosisEASL 2026: Liver and Spleen Elastography for Fibrosis Assessment
EASL 2026 will feature a Skills Learning Centre on liver and spleen elastography, highlighting its role in non-invasive fibrosis assessment.
Liver CirrhosisEASL 2026: Alcohol Policy Action Needed for Liver Disease
The European Health Alliance on Alcohol advocates for policy changes to mitigate alcohol-related liver disease, emphasizing the gap between clinical evidence and public health action.
EASL 2026 Forum: Enhancing Patient-Clinician Communication
Alcohol and Sugar: A Dual Metabolic Challenge for Patients
Metabolic Dysfunction Associated Steatotic Liver Disease: An Overview
Nearly 1 in 10 With Primary Biliary Cholangitis Have CKD
Liver-Directed Treatment Shows Efficacy in Metabolic Dysfunction
Variceal Bleeding Management: EASL 2026 Skills Centre Focuses on Endoscopic and Pharmacological Strategies
Vitamin K2 Supplementation May Curb Coronary Calcification
Evidence suggests vitamin K2 supplementation may reduce coronary artery calcification, a key marker of cardiovascular disease risk.
HypertensionHypotension Linked to Increased Alzheimer's Disease Risk
New research indicates that mid-life hypotension is a significant cardiovascular risk factor for later-life Alzheimer's disease, challenging prior assumptions.
Coronary Artery DiseaseNovel Therapies Target Atherogenic Lp(a) Particle
Emerging therapeutic strategies are shifting focus from LDL cholesterol to apoB, targeting Lp(a) and other atherogenic particles.
Heat-Attributable CVD Years of Life Lost Projected to Rise Through 2050
ESC Cardio-Oncology 2026: Key Sessions and Anticipated Focus Areas
Clopidogrel and Omeprazole: Re-evaluating Concomitant Use Risk
AI-Assisted Fetal Echocardiography Improves Early CHD Detection
5D MRI Halves Scan Time for Congenital Heart Disease Imaging
Universal Heart Failure Definition Issued by Global Societies
Medically Tailored Meals Cut HbA1c More Than Subsidies in Type 2 Diabetes
Medically tailored meals reduced HbA1c by 0.59% more than food subsidies in patients with type 2 diabetes, demonstrating superior glycemic control.
Diabetes Mellitus Type 2GLP-1 Nonresponders Often Underserved by Inadequate Dosing, Poor Adherence
Many patients labeled as GLP-1 nonresponders never receive optimal dosing or sufficient support for adherence, hindering therapeutic success.
Diabetes Mellitus Type 2Isaacs Emphasizes 'Human Touch' in Diabetes Care Beyond Technology
Diana Isaacs, PharmD, an ADA award winner, advocates for integrating empathetic, patient-centered approaches with advanced diabetes technology to improve outcomes.
GLP-1 Agonists Show Ocular Safety, Potential Therapeutic Role
Haaland's 6,000-Calorie Diet: Performance Fuel or Health Risk?
GLP-1s for Addiction: Are We There Yet?
Foundayo Confers Greater HbA1c Reduction Than Farxiga, Ozempic Pill in T2D
Unapproved Retatrutide Use Challenges Clinicians
Elecoglipron Oral GLP-1 Reduces Glucose, Weight in Phase 2
Eptinezumab Improves Cognitive Symptoms in Migraine Patients
Eptinezumab significantly reduced cognitive symptoms in patients with migraine, offering a new dimension of relief beyond headache frequency.
StrokeTBI Linked Bidirectionally With Psychiatric and Neurologic Conditions
Traumatic brain injury (TBI) shows a two-way association with various psychiatric and neurologic conditions, increasing risk for both and being influenced by their presence.
Amyotrophic Lateral SclerosisHuntington's Disease Therapy Faces Regulatory Setbacks, Clinical Impact
A novel investigational therapy for Huntington's disease has encountered significant regulatory hurdles, prompting re-evaluation of its clinical development pathway.
Migraine Linked to Increased Vascular Dementia Odds in Observational Data
Cognitive Rehabilitation Eases Long-COVID Brain Fog
New Parkinson's Drug Offers Sustained Levodopa Levels
Dopamine Agonists: A Fading Role in Parkinson's Treatment?
Creatine Supplementation: Limited Evidence for Brain Health Benefits
ML Model Predicts Epilepsy Onset in Depression, Depression in Epilepsy
New Regimen Confers 'Meaningful' Benefit in Aggressive Lymphoma
7 min readFDA Expands Casgevy for Sickle Cell in Children 2 Years and Older
8 min readMonoclonal Antibodies May Complicate Transfusion Testing
7 min readBlood Transfusion Safety: Pathogen Inactivation Reduces Transfusion-Transmitted Infections
7 min readChemo-Free Therapy Improves Outcomes in Pediatric APL (EHA 2026)
8 min readPersonalized Hemophilia Care: EHA 2026 Highlights Individualized Approaches
7 min readMacrophages: Dual Role in Haematological Malignancies Explored
7 min readMolecular Hematology: From Gene Profiles to Therapy Profiles at EHA 2026
7 min readITP Management: Bridging Clinician and Patient Perspectives
7 min readCLL: Aligning Patient Priorities with Targeted Therapy at EHA 2026
8 min read
Sleep Disruption and Fear Drive Chronic Rheumatic Pain
11 min readPodcast: Why Cheaper Humira Alternatives Face Resistance
ListenPodcast: Stopping Spinal Fusion Or Protecting The Gut?
ListenPodcast: Chasing Absolute Zero In Rheumatoid Arthritis
ListenPodcast: The ORAL Surveillance JAK Inhibitor Controversy
ListenB-Cell Dysregulation Targeted Upstream in Primary Sjögren Disease
7 min readXLH Management: Rheumatology Must Adapt at EULAR 2026
7 min readEGPA: Early Recognition & Targeted Intervention Improve Outcomes
8 min readRA Patients Face Elevated Fracture Risk: EULAR 2026 Highlights
7 min readSalivary Galectin-9 Elevated in Primary Sjögren's, Lacks Disease Activity Correlation
8 min read
Air Embolism: Two Cases After Percutaneous Lung Biopsy
7 min readSingle Question May Flag Poor Quality Sleep in Patients
9 min readPembrolizumab Reduces Pulmonary AEs vs Chemotherapy in NSCLC
8 min readDupilumab Superior to Omalizumab in High-Biomarker Asthma
7 min readATS 2026: NTM Lung Disease Detection, Therapy, QoL Advancements
8 min readBRINSUPRI® First Therapy Approved for NCFB at ATS 2026
7 min readEpithelial Cytokines Link Severe Asthma, CRSwNP, COPD at ATS 2026
8 min readTriple Therapy in Asthma: Real-World Evidence Supports Earlier Use
7 min readYUTREPIA® (treprostinil) Inhalation Powder for PH-ILD Patients
8 min readIPF/PPF: Patient and Pulmonologist Perspectives Highlight Care Gaps
8 min read
Ebola in Congo: Global Response Capacity Disappears Amidst Conflict
7 min readEbola Outbreaks Demand Swift, Coordinated Public Health Response
7 min readCOVID Vaccine Efficacy Wanes, Boosters Essential for Sustained Protection
6 min readCDC Reverses Chickenpox Vaccine Guidance, Impacting Pediatricians and Public Health
7 min readCDC Reports Rise in Deadly Tickborne Illness, Anaplasmosis Cases Up
7 min readCOVID Vaccine Efficacy in Children: A Review of Real-World Data
8 min readRifadin Syrup Under Review for Carcinogen Concerns
7 min readPublic Health Measures Significantly Reduced COVID-19 Incidence
8 min readData Integrity Concerns Raised in Pfizer's COVID-19 Vaccine Trial
7 min readVaccine Cold Chain Integrity Underpins Vaccine Security
8 min read
CAR T-Cell Therapy Nears Approval for Refractory Skin Diseases
7 min readTSW Controversy: Mitochondrial NAD Excess Identified, Diagnostic Clarity Emerges
9 min readPrior Authorization Delays Atopic Dermatitis Treatment Access
13 min readPatient-Reported Factors Redefine Alopecia Areata Severity
7 min readScalp Lesions: Rare Malignancies Mimic Benign Conditions
7 min readDown Syndrome: Skin Conditions Demand Dermatologists’ Attention
7 min readGLP-1 Receptor Agonists and Psoriatic Disease: A Deep Dive
7 min readGoat Milk Formula Linked With Less Atopic Dermatitis
7 min readParoxetine's Mechanism in Rosacea: Serotonin Pathway Clues
7 min readRemibrutinib Resolves Chronic Inducible Urticaria Symptoms
8 min read
Munich, DEAug 28 – 31UpcomingEASD 2026
Madrid, ESSep 9 – 12UpcomingERS 2026
Copenhagen, DKSep 12 – 15UpcomingESMO 2026Berlin, DESep 12 – 16UpcomingECTRIMS 2026Barcelona, ESSep 17 – 20UpcomingUEG Week 2026
Vienna, ATOct 3 – 7UpcomingAHA 2026
Chicago, USNov 7 – 9UpcomingACR 2026Washington DC, USNov 14 – 19UpcomingASH 2026New Orleans, USDec 12 – 15UpcomingACC.27 Together With WCCHouston, USApr 10 – 12PastENDO 2026Boston, USJun 13 – 16PastEHA 2026
Stockholm, SEJun 11 – 14PastEULAR 2026
London, GBJun 3 – 6PastASCO 2026Chicago, USMay 29 – Jun 2PastEASL 2026Barcelona, ESMay 27 – 30UpcomingESC 2026Munich, DEAug 28 – 31UpcomingEASD 2026Madrid, ESSep 9 – 12UpcomingERS 2026Copenhagen, DKSep 12 – 15UpcomingESMO 2026Berlin, DESep 12 – 16UpcomingECTRIMS 2026Barcelona, ESSep 17 – 20UpcomingUEG Week 2026Vienna, ATOct 3 – 7UpcomingAHA 2026Chicago, USNov 7 – 9UpcomingACR 2026Washington DC, USNov 14 – 19UpcomingASH 2026New Orleans, USDec 12 – 15UpcomingACC.27 Together With WCCHouston, USApr 10 – 12PastENDO 2026Boston, USJun 13 – 16PastEHA 2026Stockholm, SEJun 11 – 14PastEULAR 2026London, GBJun 3 – 6PastASCO 2026Chicago, USMay 29 – Jun 2PastEASL 2026Barcelona, ESMay 27 – 30
CAR T: Speed and Reliability Critical for Patient Outcomes
Avapritinib Improves Outcomes in Nonadvanced and Advanced Systemic Mastocytosis
Cancer Care Disparities Highlighted in Crisis, Displaced Populations
Desiccated Thyroid Extract: Efficacy and Safety in Hypothyroidism
DLBCL Relapse: EHA 2026 Addresses Gaps in Treatment Strategy
Subcutaneous Immunotherapy Offers Alternative Administration at ASCO 2026
EASL 2026 Forum: Enhancing Patient-Clinician Communication
CLL: EHA 2026 to Address Unmet Needs in Treatment Selection
CAR T Cell Therapy Shows Promise in SLE and SSc Immune Reset
XLH Management: Rheumatology Must Adapt at EULAR 2026
Radiopharmaceutical Therapy: Improving Effectiveness, Access, and Safety
Early Intervention Crucial for Inflammatory Joint Disease, Osteoporosis
TACE + Camrelizumab/Rivoceranib Improves OS in Unresectable HCC
AML Treatment Strategies: Optimising Outcomes in a Complex Disease
Few Pediatric Cancer Drugs Reach Phase 3 or Approval
Korlym® Improves Cushing's Syndrome Symptoms in Patient Experience Data
MASLD Diagnosis Faces Barriers Despite 2024 EASL Guidelines
Macrophages: Dual Role in Haematological Malignancies Explored
TRUQAP + Fulvestrant: 2L Option for HR+/HER2- aBC/mBC with PI3K-AKT Alterations
EULAR 2026: Psoriatic Disease Spectrum Highlights
PEAK Study Shows Novel Agent Improves PFS in Advanced GIST
AML: Fitness, Not Age, Predicts IC Eligibility at EHA 2026
GLP-1 RAs Reduce CV Risk in T2D Via Weight, Glucose Pathways
RA Care: Navigating Treatment Choices at EULAR 2026
Myelofibrosis Management: Cytopenia Guides Treatment at EHA 2026
EULAR 2026: Methotrexate Remains Cornerstone in RA First-Line
Triple Therapy in Asthma: Real-World Evidence Supports Earlier Use
Inluriyo™ and Verzenio® Presentations at ASCO 2026
Systemic Sclerosis: EULAR 2026 Highlights Diagnosis, Prognosis
Symptom Science Integration Improves Cancer Outcomes at ASCO 2026
Novel Approaches in R/R MM: Expert Perspectives from EHA 2026
BCMA-Directed Therapies Show Efficacy in Relapsed/Refractory Multiple Myeloma
Molecular Hematology: From Gene Profiles to Therapy Profiles at EHA 2026
IL-33's Dual Role in COPD: Inflammation and Mucus Dysfunction
Multidisciplinary Approach Improves Autoimmune ILD Management
DLBCL Management: Bispecific Antibodies as Emerging Therapeutic Option
EASL Congress 2026: Key Trials to Watch in Liver Disease Management
Caplacizumab Improves iTTP Outcomes in Real-World Settings
Immuno-Fibrotic Crosstalk: A New Target in Rheumatology
CD38 mAb Quad Therapy: Subcutaneous Dosing Reduces Burden
Triple Therapy Optimises COPD Outcomes at ATS 2026
Multimodal OSA Treatment: Nerve Stimulation, Surgery, Oral Appliances
Sarcoidosis: Current Understanding of Diagnosis and Management
CAR T Therapy Shows Sustained Efficacy in Relapsed/Refractory Lymphoma
CAR T in DLBCL: Optimising Patient Outcomes at EHA 2026
Pediatric Pulmonary Research Gaps Highlighted for Global Health
Bispecific Antibodies Efficacious in Multiple Myeloma with Renal Impairment
Fixed-Duration BCL-2 Combo Offers Time Off Treatment in 1L CLL
FLT3mut+ AML Outcomes: EHA 2026 Reviews Current Strategies
Late-Onset Genetic Cholestasis: Underdiagnosis in Adults Examined
ATS 2026: Addressing the Cough Assessment Gap in Respiratory Disease
AML: Fitness, Not Age, Predicts Intensive Chemotherapy Eligibility
Tafasitamab-R-CHOP Boosts Frontline DLBCL Outcomes at ASCO 2026
IKT-001 Adaptive Study Programme for Pulmonary Arterial Hypertension
ANCA Vasculitis: Evolving Strategies Target Remission & Relapse Prevention
Peer Insights on Once-Daily Weight Management Therapy at endo 2026
HYRNUO® (Sevabertinib) Shows Efficacy in Advanced Solid Tumours
ATS 2026: NTM Lung Disease Detection, Therapy, QoL Advancements
HTAN Decodes Tumor Evolution: Ecological Perspective at AACR2026
Next-Gen Extracellular Vesicles: Biomarkers, Targets, Deliverables in Oncology
MAVEs Inform Variant Interpretation in Clinical Oncology Practice
Infection Prevention Critical in Hematological Malignancies
CAR T Cell Therapy Shows Efficacy in Autoimmune Diseases at EULAR 2026
Cancer Elimination at ASCO 2026: Aspirational Goals and Current Realities
Early Intervention in SLE/LN Reduces Long-Term Damage
Multiple Myeloma: Aligning Innovation with Clinical Practice at EHA 2026
A-TANGO Score Refines ACLF Diagnosis, Prognosis in Cirrhosis
Autoantibodies: Hidden Drivers of Autoimmune Rheumatic Diseases
AI Algorithms Enhance Pulmonary Disease Management at ATS 2026
Defining Hyperphagia Treatment Possibilities in Prader-Willi Syndrome
CD19+ B-Cell Targeting Shows Efficacy in IgG4-RD Management
NDMM Treatment Optimisation: Communication Key to Individualisation
ATS 2026: Lung Cancer Management Advances in Targeted Therapy
Classic CAH: New Approaches to Glucocorticoid Dosing
Cushing's Syndrome: Addressing Diagnostic Delays and Treatment Gaps
Inflammation Drives Sickle Cell Disease Pathophysiology
Desmopressin Dosing Refined for Central Diabetes Insipidus
B-Cell Dysregulation Targeted Upstream in Primary Sjögren Disease
Yoga Reduces Insomnia, Fatigue, Anxiety in Cancer Survivors
ILD Diagnosis and Management: A Practical ATS 2026 Update
AI in Hematology: EHA 2026 Focuses on Practical, Ethical Integration
EASL 2026 Consensus: AATD-Liver Disease Management Standardised
RA Patients Face Elevated Fracture Risk: EULAR 2026 Highlights
Real-World Data Confirms Proximal Complement Inhibition in PNH
CLL First-Line Therapy: Case-Based Insights from EHA 2026
Early SLE Disease Control: Targeting IFN Pathway at EULAR 2026
JAK Inhibitor Combinations Show Efficacy in Myelofibrosis at EHA 2026
Eosinophilic Disorders: Best Practices for HES and EGPA at ATS 2026
ASCO 2026 May 31st Program Highlights: Focus on Novel Immunotherapies
ICI Dissemination Challenges Highlighted at ASCO 2026
Novel Approaches Address Multiple Myeloma Resistance at EHA 2026
ATS 2026: Ultrasound Education Advances for Clinical Practice
Hypothyroidism: Symptom Burden Persists Despite Euthyroidism
Right Heart Catheterization: ATS 2026 Clarifies Waveform Interpretation
Oncodetect® MRD Test Shows Analytical Validity, Clinical Utility at ASCO
EHA 2026: Anticipating Advances in Haematological Malignancies
SpA Remission: Clinical Symptoms vs. Subclinical Inflammation at EULAR 2026
Doctor-Patient Communication Improves Treatment Acceptance in Cancer
Multidisciplinary Care Improves Spondyloarthritis Outcomes
Lupus Management: Progress and Persistent Challenges at EULAR 2026
Tile Radiation for Large Brain Mets: A New Approach at ASCO 2026
Acute Respiratory Failure: Lifespan Phenotypes and Trajectories
MASH Diagnosis: Non-Invasive Markers Show Promise at EASL 2026
Biomarkers and Novel Treatments Highlight Prostate Cancer Advances at ASCO
NK Cell Immunotherapy: Biology to Clinic at AACR 2026
ASCO 2026 May 30th Program Highlights: Immunotherapy Advances in Solid Tumors
Evolving Infection Prevention in HSCT and Cellular Therapies
Acromegaly Management: Focus on Biochemical Control at ENDO 2026
Early Breast Cancer at ASCO 2026: Trials to Watch
How Immunotherapy Unmasks Invisible Lung Cancer
ASCO 2026: Anticipating Advances in Oncology Treatment
CML Survivorship: Beyond Survival to Quality of Life
Salivary Galectin-9 Elevated in Primary Sjögren's, Lacks Disease Activity Correlation
AATD: Aiming for AAT Restoration and Clinically Meaningful Endpoints
Infection Prevention Critical in Hematological Malignancies
Epithelial Dysfunction: A Unified Target in Airway Disease Management
ITP Management: Bridging Clinician and Patient Perspectives
IPF/PPF: Patient and Pulmonologist Perspectives Highlight Care Gaps
AML: Rethinking Intensive Therapy for Myelodysplasia-Related & Therapy-Related Subtypes
ASCO 2026 June 1st Program Highlights: Novel Immunotherapy Data
Treat-to-Target in SLE: Balancing Burden, Benefit, and Risk
AIRSUPRA® Reduces Asthma Exacerbations in ATS 2026 Data
Bispecific Antibodies Show Promise in Relapsed/Refractory Multiple Myeloma
Immune Drivers in Autoimmune Cytopenias Inform Patient Care
Personalized Hemophilia Care: EHA 2026 Highlights Individualized Approaches
EASL 2026: Liver and Spleen Elastography for Fibrosis Assessment
AI, Wearables Transform Sleep Diagnostics: ATS 2026 Preview
YUTREPIA® (treprostinil) Inhalation Powder for PH-ILD Patients
EULAR 2026: Polymyalgia Rheumatica Guidelines Incorporate RWE
Belantamab Mafodotin's Evolving Role in RRMM: EHA 2026 Insights
Early AxSpA Diagnosis: Case-Based Discussion at EULAR 2026
Immunological Insights Inform ILD & Transplant Outcomes
Hypoparathyroidism Treatment: Patient, Care Partner, HCP Perspectives
ASCO 2026 May 29th Program Highlights: Novel Oncology Therapies
IDH1m AML: Ivosidenib Plus Azacitidine Improves OS by 12.5 Months
Contagion: Acute Respiratory Failure Cases Highlight Ventilator Management
Optimising Transplant in Haemoglobinopathies: EHA 2026 Perspectives
Immunotherapy and Targeted Therapy: New Data from ASCO 2026
MASH Advanced Fibrosis: Experts Detail Unique Challenges at EASL 2026
CD20-Targeted Therapies Remain Central to NHL Management
Tirzepatide: Efficacy in Weight Management Explored at ATS 2026
HER2-Expressing Breast Cancer: Advancements in Targeted Therapies
EASL 2026: PSC Therapies Advance Beyond Symptom Management
Low Alkaline Phosphatase: Recognizing Clinical Consequences
Chemo-Free Therapy Improves Outcomes in Pediatric APL (EHA 2026)
ATS 2026: Bronchiectasis and NTM Pulmonary Disease Management
EASL 2026: Alcohol Policy Action Needed for Liver Disease
CLL: Aligning Patient Priorities with Targeted Therapy at EHA 2026
DLBCL Treatment: Emerging Targeted Therapies at EHA 2026
Outsmarting Shape-Shifting Lung Cancer Resistance
Allogeneic Cell Therapy for EBV+ PTLD: EHA 2026 Insights
Bispecific Antibodies Positioned in Relapsed Follicular Lymphoma
Novel Biomarkers Improve Pediatric Solid Tumor Detection
RA Treatment Optimisation: Applying Two Decades of Progress
Optimising PsA and axSpA Treatment: EULAR 2026 Focuses on Early Intervention
Bispecific Antibodies in FL: EHA 2026 Explores Advancing Outcomes
New 2L+ Combination Therapy Shows Efficacy in RRMM Post-PI/IMiD
Cancer Therapies Induce Lifespan Comorbidities: ACCR 2026 Review
AI Foundation Models Enhance Diagnostic Insights in Oncology
More Breast Cancer Patients Can Skip Axillary Dissection
FLT3 Inhibitors Improve AML Outcomes Pre- and Post-Transplant
EGPA: Early Recognition & Targeted Intervention Improve Outcomes
CPET Advances Refine Cardiopulmonary Disease Assessment at ATS 2026
Endocrinologists' Role in Early Thyroid Eye Disease Recognition
Severe Asthma: Beyond Airway Focus in Treatment Decisions at ATS 2026
BTK Inhibitors in CLL: Evolving Landscape and Sequential Strategies
Ventilator Management: Foundations for Bedside Implementation
JASCAYD® (nerandomilast) Offers New Therapeutic Option for COPD
Bronchoscopy Training: ATS 2026 Focuses on EBUS and Guided Techniques
Optimizing Frontline LR-MDS Treatment: EHA 2026 Data Review
HDV Management: EASL 2026 Highlights PegIFN-α as Standard
Pediatric Advanced Bronchoscopy: Precision in Airway Management
NDMM Treatment Advances: Quadruplet Regimens Show Efficacy
SLE Pathophysiology Advances Inform Future Precision Care at EULAR 2026
Severe Hypoglycemia in T1D: Enhancing Patient-Clinician Dialogue
New Biologic Offers Option for Severe Eosinophilic Asthma
Early ILD Recognition in SARD/SSc: Drivers of Progression and Workflow Solutions
AAT Protein's Role in Lung Health Beyond COPD & Severe Asthma
Liver-Directed Treatment Shows Efficacy in Metabolic Dysfunction
CAR T-Cell Therapy Guidelines Evolve for Lymphoma, Myeloma at EHA 2026
Novel Therapies Improve Outcomes Post-cBTKi in CLL at EHA 2026
CELMoDs Show Promise in Relapsed/Refractory Multiple Myeloma
Iron Status Clarifies Erythrocytosis, Symptoms in Polycythemia Vera
12 Months of Romosozumab Builds Bone Density in Postmenopausal Osteoporosis
VEXAS Syndrome: Expert Consensus on Multidisciplinary Care at EULAR 2026
MRD Status Guides First-Line Treatment Duration in Haematologic Malignancies
Afirma Molecular Testing: Unique Situations and New Prognostic Development
Endo 2026: Risk-Based Osteoporosis Management Refines Clinical Practice
Myriad's Precise MRD™ Test Shows Ultra-Sensitive Detection at ASCO 2026
AI in Oncology: Practical Applications Transforming Cancer Care
CLL First-Line Treatment: BTK Inhibitors vs. Venetoclax Combinations
Steroidogenesis Inhibitor Targets Root Cause of Cushing’s Syndrome
Rapid SLE Control Prevents Organ Damage: EULAR 2026 Focus
DLBCL Treatment Sequencing: EHA 2026 Explores Current Therapies
Obesity Management Improves Psoriatic Disease Outcomes
EULAR 2026: Earlier AxSpA Recognition Improves Disease Burden
Bispecific Antibodies Show Promise in Relapsed/Refractory Haematological Malignancies
TLR7/8 Inhibition Offers New Lupus Perspective at EULAR 2026
BCMA Bispecifics Transition to Community Myeloma Care: EHA 2026
XLH Adults: Osteomalacia Persists Despite Conventional Therapy
MLVs: Dual Role in Brain Metastases Offers Therapeutic Targets
Epithelial Cytokines Link Severe Asthma, CRSwNP, COPD at ATS 2026
Sjögren’s Disease: Targeting Underlying Activity Beyond Symptoms
AI Integration Improves Lung Cancer MDT Workflow at ATS 2026
DNA Methylation Patterns Emerge as Sarcoma Biomarkers
Allogeneic Cell Therapy for EBV+ PTLD: EHA 2026 Insights
Rare Conditions: EHA 2026 Highlights Diagnostic Challenges
Variceal Bleeding Management: EASL 2026 Skills Centre Focuses on Endoscopic and Pharmacological Strategies
Hypercortisolism: Emerging Diagnostic and Management Insights
MCED Tests Show Promise for Earlier Cancer Detection at ASCO 2026
Obesity Care: Tailored Treatment Strategies Highlighted at endo 2026
EASL 2026: Non-invasive Diagnostics Advance Liver Disease Staging
BRINSUPRI® First Therapy Approved for NCFB at ATS 2026
CAR T: Speed and Reliability Critical for Patient Outcomes
Avapritinib Improves Outcomes in Nonadvanced and Advanced Systemic Mastocytosis
Cancer Care Disparities Highlighted in Crisis, Displaced Populations
Desiccated Thyroid Extract: Efficacy and Safety in Hypothyroidism
DLBCL Relapse: EHA 2026 Addresses Gaps in Treatment Strategy
Subcutaneous Immunotherapy Offers Alternative Administration at ASCO 2026
EASL 2026 Forum: Enhancing Patient-Clinician Communication
CLL: EHA 2026 to Address Unmet Needs in Treatment Selection
CAR T Cell Therapy Shows Promise in SLE and SSc Immune Reset
XLH Management: Rheumatology Must Adapt at EULAR 2026
Radiopharmaceutical Therapy: Improving Effectiveness, Access, and Safety
Early Intervention Crucial for Inflammatory Joint Disease, Osteoporosis
TACE + Camrelizumab/Rivoceranib Improves OS in Unresectable HCC
AML Treatment Strategies: Optimising Outcomes in a Complex Disease
Few Pediatric Cancer Drugs Reach Phase 3 or Approval
Korlym® Improves Cushing's Syndrome Symptoms in Patient Experience Data
MASLD Diagnosis Faces Barriers Despite 2024 EASL Guidelines
Macrophages: Dual Role in Haematological Malignancies Explored
TRUQAP + Fulvestrant: 2L Option for HR+/HER2- aBC/mBC with PI3K-AKT Alterations
EULAR 2026: Psoriatic Disease Spectrum Highlights
PEAK Study Shows Novel Agent Improves PFS in Advanced GIST
AML: Fitness, Not Age, Predicts IC Eligibility at EHA 2026
GLP-1 RAs Reduce CV Risk in T2D Via Weight, Glucose Pathways
RA Care: Navigating Treatment Choices at EULAR 2026
Myelofibrosis Management: Cytopenia Guides Treatment at EHA 2026
EULAR 2026: Methotrexate Remains Cornerstone in RA First-Line
Triple Therapy in Asthma: Real-World Evidence Supports Earlier Use
Inluriyo™ and Verzenio® Presentations at ASCO 2026
Systemic Sclerosis: EULAR 2026 Highlights Diagnosis, Prognosis
Symptom Science Integration Improves Cancer Outcomes at ASCO 2026
Novel Approaches in R/R MM: Expert Perspectives from EHA 2026
BCMA-Directed Therapies Show Efficacy in Relapsed/Refractory Multiple Myeloma
Molecular Hematology: From Gene Profiles to Therapy Profiles at EHA 2026
IL-33's Dual Role in COPD: Inflammation and Mucus Dysfunction
Multidisciplinary Approach Improves Autoimmune ILD Management
DLBCL Management: Bispecific Antibodies as Emerging Therapeutic Option
EASL Congress 2026: Key Trials to Watch in Liver Disease Management
Caplacizumab Improves iTTP Outcomes in Real-World Settings
Immuno-Fibrotic Crosstalk: A New Target in Rheumatology
CD38 mAb Quad Therapy: Subcutaneous Dosing Reduces Burden
Triple Therapy Optimises COPD Outcomes at ATS 2026
Multimodal OSA Treatment: Nerve Stimulation, Surgery, Oral Appliances
Sarcoidosis: Current Understanding of Diagnosis and Management
CAR T Therapy Shows Sustained Efficacy in Relapsed/Refractory Lymphoma
CAR T in DLBCL: Optimising Patient Outcomes at EHA 2026
Pediatric Pulmonary Research Gaps Highlighted for Global Health
Bispecific Antibodies Efficacious in Multiple Myeloma with Renal Impairment
Fixed-Duration BCL-2 Combo Offers Time Off Treatment in 1L CLL
FLT3mut+ AML Outcomes: EHA 2026 Reviews Current Strategies
Late-Onset Genetic Cholestasis: Underdiagnosis in Adults Examined
ATS 2026: Addressing the Cough Assessment Gap in Respiratory Disease
AML: Fitness, Not Age, Predicts Intensive Chemotherapy Eligibility
Tafasitamab-R-CHOP Boosts Frontline DLBCL Outcomes at ASCO 2026
IKT-001 Adaptive Study Programme for Pulmonary Arterial Hypertension
ANCA Vasculitis: Evolving Strategies Target Remission & Relapse Prevention
Peer Insights on Once-Daily Weight Management Therapy at endo 2026
HYRNUO® (Sevabertinib) Shows Efficacy in Advanced Solid Tumours
ATS 2026: NTM Lung Disease Detection, Therapy, QoL Advancements
HTAN Decodes Tumor Evolution: Ecological Perspective at AACR2026
Next-Gen Extracellular Vesicles: Biomarkers, Targets, Deliverables in Oncology
MAVEs Inform Variant Interpretation in Clinical Oncology Practice
Infection Prevention Critical in Hematological Malignancies
CAR T Cell Therapy Shows Efficacy in Autoimmune Diseases at EULAR 2026
Cancer Elimination at ASCO 2026: Aspirational Goals and Current Realities
Early Intervention in SLE/LN Reduces Long-Term Damage
Multiple Myeloma: Aligning Innovation with Clinical Practice at EHA 2026
A-TANGO Score Refines ACLF Diagnosis, Prognosis in Cirrhosis
Autoantibodies: Hidden Drivers of Autoimmune Rheumatic Diseases
AI Algorithms Enhance Pulmonary Disease Management at ATS 2026
Defining Hyperphagia Treatment Possibilities in Prader-Willi Syndrome
CD19+ B-Cell Targeting Shows Efficacy in IgG4-RD Management
NDMM Treatment Optimisation: Communication Key to Individualisation
ATS 2026: Lung Cancer Management Advances in Targeted Therapy
Classic CAH: New Approaches to Glucocorticoid Dosing
Cushing's Syndrome: Addressing Diagnostic Delays and Treatment Gaps
Inflammation Drives Sickle Cell Disease Pathophysiology
Desmopressin Dosing Refined for Central Diabetes Insipidus
B-Cell Dysregulation Targeted Upstream in Primary Sjögren Disease
Yoga Reduces Insomnia, Fatigue, Anxiety in Cancer Survivors
ILD Diagnosis and Management: A Practical ATS 2026 Update
AI in Hematology: EHA 2026 Focuses on Practical, Ethical Integration
EASL 2026 Consensus: AATD-Liver Disease Management Standardised
RA Patients Face Elevated Fracture Risk: EULAR 2026 Highlights
Real-World Data Confirms Proximal Complement Inhibition in PNH
CLL First-Line Therapy: Case-Based Insights from EHA 2026
Early SLE Disease Control: Targeting IFN Pathway at EULAR 2026
JAK Inhibitor Combinations Show Efficacy in Myelofibrosis at EHA 2026
Eosinophilic Disorders: Best Practices for HES and EGPA at ATS 2026
ASCO 2026 May 31st Program Highlights: Focus on Novel Immunotherapies
ICI Dissemination Challenges Highlighted at ASCO 2026
Novel Approaches Address Multiple Myeloma Resistance at EHA 2026
ATS 2026: Ultrasound Education Advances for Clinical Practice
Hypothyroidism: Symptom Burden Persists Despite Euthyroidism
Right Heart Catheterization: ATS 2026 Clarifies Waveform Interpretation
Oncodetect® MRD Test Shows Analytical Validity, Clinical Utility at ASCO
EHA 2026: Anticipating Advances in Haematological Malignancies
SpA Remission: Clinical Symptoms vs. Subclinical Inflammation at EULAR 2026
Doctor-Patient Communication Improves Treatment Acceptance in Cancer
Multidisciplinary Care Improves Spondyloarthritis Outcomes
Lupus Management: Progress and Persistent Challenges at EULAR 2026
Tile Radiation for Large Brain Mets: A New Approach at ASCO 2026
Acute Respiratory Failure: Lifespan Phenotypes and Trajectories
MASH Diagnosis: Non-Invasive Markers Show Promise at EASL 2026
Biomarkers and Novel Treatments Highlight Prostate Cancer Advances at ASCO
NK Cell Immunotherapy: Biology to Clinic at AACR 2026
ASCO 2026 May 30th Program Highlights: Immunotherapy Advances in Solid Tumors
Evolving Infection Prevention in HSCT and Cellular Therapies
Acromegaly Management: Focus on Biochemical Control at ENDO 2026
Early Breast Cancer at ASCO 2026: Trials to Watch
How Immunotherapy Unmasks Invisible Lung Cancer
ASCO 2026: Anticipating Advances in Oncology Treatment
CML Survivorship: Beyond Survival to Quality of Life
Salivary Galectin-9 Elevated in Primary Sjögren's, Lacks Disease Activity Correlation
AATD: Aiming for AAT Restoration and Clinically Meaningful Endpoints
Infection Prevention Critical in Hematological Malignancies
Epithelial Dysfunction: A Unified Target in Airway Disease Management
ITP Management: Bridging Clinician and Patient Perspectives
IPF/PPF: Patient and Pulmonologist Perspectives Highlight Care Gaps
AML: Rethinking Intensive Therapy for Myelodysplasia-Related & Therapy-Related Subtypes
ASCO 2026 June 1st Program Highlights: Novel Immunotherapy Data
Treat-to-Target in SLE: Balancing Burden, Benefit, and Risk
AIRSUPRA® Reduces Asthma Exacerbations in ATS 2026 Data
Bispecific Antibodies Show Promise in Relapsed/Refractory Multiple Myeloma
Immune Drivers in Autoimmune Cytopenias Inform Patient Care
Personalized Hemophilia Care: EHA 2026 Highlights Individualized Approaches
EASL 2026: Liver and Spleen Elastography for Fibrosis Assessment
AI, Wearables Transform Sleep Diagnostics: ATS 2026 Preview
YUTREPIA® (treprostinil) Inhalation Powder for PH-ILD Patients
EULAR 2026: Polymyalgia Rheumatica Guidelines Incorporate RWE
Belantamab Mafodotin's Evolving Role in RRMM: EHA 2026 Insights
Early AxSpA Diagnosis: Case-Based Discussion at EULAR 2026
Immunological Insights Inform ILD & Transplant Outcomes
Hypoparathyroidism Treatment: Patient, Care Partner, HCP Perspectives
ASCO 2026 May 29th Program Highlights: Novel Oncology Therapies
IDH1m AML: Ivosidenib Plus Azacitidine Improves OS by 12.5 Months
Contagion: Acute Respiratory Failure Cases Highlight Ventilator Management
Optimising Transplant in Haemoglobinopathies: EHA 2026 Perspectives
Immunotherapy and Targeted Therapy: New Data from ASCO 2026
MASH Advanced Fibrosis: Experts Detail Unique Challenges at EASL 2026
CD20-Targeted Therapies Remain Central to NHL Management
Tirzepatide: Efficacy in Weight Management Explored at ATS 2026
HER2-Expressing Breast Cancer: Advancements in Targeted Therapies
EASL 2026: PSC Therapies Advance Beyond Symptom Management
Low Alkaline Phosphatase: Recognizing Clinical Consequences
Chemo-Free Therapy Improves Outcomes in Pediatric APL (EHA 2026)
ATS 2026: Bronchiectasis and NTM Pulmonary Disease Management
EASL 2026: Alcohol Policy Action Needed for Liver Disease
CLL: Aligning Patient Priorities with Targeted Therapy at EHA 2026
DLBCL Treatment: Emerging Targeted Therapies at EHA 2026
Outsmarting Shape-Shifting Lung Cancer Resistance
Allogeneic Cell Therapy for EBV+ PTLD: EHA 2026 Insights
Bispecific Antibodies Positioned in Relapsed Follicular Lymphoma
Novel Biomarkers Improve Pediatric Solid Tumor Detection
RA Treatment Optimisation: Applying Two Decades of Progress
Optimising PsA and axSpA Treatment: EULAR 2026 Focuses on Early Intervention
Bispecific Antibodies in FL: EHA 2026 Explores Advancing Outcomes
New 2L+ Combination Therapy Shows Efficacy in RRMM Post-PI/IMiD
Cancer Therapies Induce Lifespan Comorbidities: ACCR 2026 Review
AI Foundation Models Enhance Diagnostic Insights in Oncology
More Breast Cancer Patients Can Skip Axillary Dissection
FLT3 Inhibitors Improve AML Outcomes Pre- and Post-Transplant
EGPA: Early Recognition & Targeted Intervention Improve Outcomes
CPET Advances Refine Cardiopulmonary Disease Assessment at ATS 2026
Endocrinologists' Role in Early Thyroid Eye Disease Recognition
Severe Asthma: Beyond Airway Focus in Treatment Decisions at ATS 2026
BTK Inhibitors in CLL: Evolving Landscape and Sequential Strategies
Ventilator Management: Foundations for Bedside Implementation
JASCAYD® (nerandomilast) Offers New Therapeutic Option for COPD
Bronchoscopy Training: ATS 2026 Focuses on EBUS and Guided Techniques
Optimizing Frontline LR-MDS Treatment: EHA 2026 Data Review
HDV Management: EASL 2026 Highlights PegIFN-α as Standard
Pediatric Advanced Bronchoscopy: Precision in Airway Management
NDMM Treatment Advances: Quadruplet Regimens Show Efficacy
SLE Pathophysiology Advances Inform Future Precision Care at EULAR 2026
Severe Hypoglycemia in T1D: Enhancing Patient-Clinician Dialogue
New Biologic Offers Option for Severe Eosinophilic Asthma
Early ILD Recognition in SARD/SSc: Drivers of Progression and Workflow Solutions
AAT Protein's Role in Lung Health Beyond COPD & Severe Asthma
Liver-Directed Treatment Shows Efficacy in Metabolic Dysfunction
CAR T-Cell Therapy Guidelines Evolve for Lymphoma, Myeloma at EHA 2026
Novel Therapies Improve Outcomes Post-cBTKi in CLL at EHA 2026
CELMoDs Show Promise in Relapsed/Refractory Multiple Myeloma
Iron Status Clarifies Erythrocytosis, Symptoms in Polycythemia Vera
12 Months of Romosozumab Builds Bone Density in Postmenopausal Osteoporosis
VEXAS Syndrome: Expert Consensus on Multidisciplinary Care at EULAR 2026
MRD Status Guides First-Line Treatment Duration in Haematologic Malignancies
Afirma Molecular Testing: Unique Situations and New Prognostic Development
Endo 2026: Risk-Based Osteoporosis Management Refines Clinical Practice
Myriad's Precise MRD™ Test Shows Ultra-Sensitive Detection at ASCO 2026
AI in Oncology: Practical Applications Transforming Cancer Care
CLL First-Line Treatment: BTK Inhibitors vs. Venetoclax Combinations
Steroidogenesis Inhibitor Targets Root Cause of Cushing’s Syndrome
Rapid SLE Control Prevents Organ Damage: EULAR 2026 Focus
DLBCL Treatment Sequencing: EHA 2026 Explores Current Therapies
Obesity Management Improves Psoriatic Disease Outcomes
EULAR 2026: Earlier AxSpA Recognition Improves Disease Burden
Bispecific Antibodies Show Promise in Relapsed/Refractory Haematological Malignancies
TLR7/8 Inhibition Offers New Lupus Perspective at EULAR 2026
BCMA Bispecifics Transition to Community Myeloma Care: EHA 2026
XLH Adults: Osteomalacia Persists Despite Conventional Therapy
MLVs: Dual Role in Brain Metastases Offers Therapeutic Targets
Epithelial Cytokines Link Severe Asthma, CRSwNP, COPD at ATS 2026
Sjögren’s Disease: Targeting Underlying Activity Beyond Symptoms
AI Integration Improves Lung Cancer MDT Workflow at ATS 2026
DNA Methylation Patterns Emerge as Sarcoma Biomarkers
Allogeneic Cell Therapy for EBV+ PTLD: EHA 2026 Insights
Rare Conditions: EHA 2026 Highlights Diagnostic Challenges
Variceal Bleeding Management: EASL 2026 Skills Centre Focuses on Endoscopic and Pharmacological Strategies
Hypercortisolism: Emerging Diagnostic and Management Insights
MCED Tests Show Promise for Earlier Cancer Detection at ASCO 2026
Obesity Care: Tailored Treatment Strategies Highlighted at endo 2026
EASL 2026: Non-invasive Diagnostics Advance Liver Disease Staging
BRINSUPRI® First Therapy Approved for NCFB at ATS 2026
